This Article Full Text (OnlineFirst PDF) All Versions of this Article: 1076029609338711v1 15/5/501    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Scopus Google Scholar Articles by Adiguzel, C. Articles by Fareed, J. PubMed PubMed Citation Articles by Adiguzel, C. Articles by Fareed, J. Social Bookmarking                         What's this?

Comparative Anticoagulant and Platelet Modulatory Effects of Enoxaparin and Sulodexide

^* To whom correspondence should be addressed. E-mail: cadiguzel{at}lumc.edu.

	Abstract

Sulodexide represents a novel antithrombotic agent with multiple sites of action on blood coagulation and vascular processes. The purpose of this study was to compare sulodexide and enoxaparin on anticoagulant effects, tissue factor (TF)-induced activation of platelets, inhibition of microparticle generation and to investigate their effect on heparin-induced platelet aggregation (HIPA). Sulodexide was compared with enoxaparin at equigravimetric concentrations. When compared to enoxaparin, sulodexide produced a stronger anticoagulant effect in the prothrombin time (PT), activated partial thromboplastin time (APTT), Heptest, and thrombin time (TT) assays. In addition, sulodexide had a stronger inhibitory effect on TF-mediated microparticle generation (IC₅₀ = 2.8 µg/mL), P-selectin expression (IC₅₀ = 4.8 µg/ml), and platelet aggregate formation (IC₅₀ = 8.5 µg/mL) compared to higher IC₅₀ values with enoxaparin. Sulodexide and enoxaparin exhibited a similar effect on heparin-induced thrombocytopenia (HIT) antibody-mediated platelet activation HIPA assays. These results suggest that sulodexide is a relatively stronger anticoagulant agent than enoxaparin. Sulodexide is subcutaneously absorbed. Its ability to inhibit TF-mediated platelet activation may contribute to the observed therapeutic effects of sulodexide in microvascular vasculopathy such as diabetic nephropathy. These results also suggest that inhibition of TF activation of platelets by sulodexide may be independent of its anticoagulant effects. These results warrant further investigation of sulodexide in additional preclinical and clinical studies.

First published on August 23, 2009, doi:10.1177/1076029609338711

Clinical and Applied Thrombosis/Hemostasis 2009;15:501.

A more recent version of this article appeared on October 1, 2009


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?